Mean plasma glucose concentrations over time with BAQSIMI in patients ages 4 to <18
BAQSIMI DEMONSTRATED COMPARABLE EFFICACY TO INJECTABLE GLUCAGON IN PEDIATRIC PATIENTS WITH TYPE 1 DIABETES
Treatment success for BAQSIMI and injectable glucagon*
Prior to treatment, insulin was used to reduce blood glucose levels. Treatment success was defined as the percentage of patients with a glucose increase of ≥1.1 mmol/L from the glucose nadir within 30 minutes of glucagon administration.
Nasal congestion does not impact the absorption of BAQSIMI
* Study IGBB was a randomized, multicenter, open-label clinical study that assessed BAQSIMI compared to intra-muscular glucagon in pediatric patients aged 4 years and older with type 1 diabetes. Insulin was used to reduce blood glucose levels, and glucagon was administered after glucose reached <4.4 mmol/L on the dosing day.
Click here to download the full study publication
† Patients aged 4 to <8 years (n=12), 8 to <12 years (n=12), and 12 to <18 years (n=12).
‡ Patients aged 4 to <8 years (n=6), 8 to <12 years (n=6), and 12 to <18 years (n=12).